OncoMatch/Clinical Trials/NCT05691010
A Study of Short-Course Radiation Therapy With Chemotherapy in People With Endometrial Cancer
Is NCT05691010 recruiting? Yes, currently enrolling (Sep 2026). This Early Phase 1 trial studies multiple treatments including Carboplatin and Paclitaxel for endometrial cancer.
Treatment: Carboplatin · Paclitaxel — The purpose of this study is to find out whether short-course radiation therapy (1 week instead of the usual 5 weeks) with chemotherapy (carboplatin and paclitaxel) is practical (feasible), meaning that most participants are able to complete the treatment schedule.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Cancer type
Endometrial Cancer
Biomarker criteria
Excluded: POLE pathogenic mutation
endometrial cancers harbor known pathogenic POLE mutations
Excluded: MLH1 loss
endometrial cancers are mismatch repair deficient, as determined by immunohistochemical staining for MLH1, PMS2, MSH2, and MSH6
Excluded: PMS2 loss
endometrial cancers are mismatch repair deficient, as determined by immunohistochemical staining for MLH1, PMS2, MSH2, and MSH6
Excluded: MSH2 loss
endometrial cancers are mismatch repair deficient, as determined by immunohistochemical staining for MLH1, PMS2, MSH2, and MSH6
Excluded: MSH6 loss
endometrial cancers are mismatch repair deficient, as determined by immunohistochemical staining for MLH1, PMS2, MSH2, and MSH6
Excluded: MSI high
endometrial cancers are mismatch repair deficient, as determined by ... and/or MSI-H
Disease stage
Required: Stage FIGO (2009) STAGE IIIA, FIGO (2009) STAGE IIIC1 (other)
FIGO (2009) stage IIIA or IIIC1 disease (as determined by surgical staging)
Demographics
Prior therapy
Cannot have received: radiation therapy
No prior radiation therapy ... for treatment of endometrial cancer
Cannot have received: chemotherapy
No prior ... chemotherapy for treatment of endometrial cancer
Cannot have received: radiation therapy
Patients with a history of pelvic radiation
Lab requirements
Blood counts
ANC ≥ 1500/mcL; Platelet count ≥ 100,000/mcL
Kidney function
Creatinine ≤ 1.5X ULN
Liver function
AST/ALT ≤ 3X ULN; total bilirubin ≤ 1.5X ULN (≤ 3X ULN if Gilbert's disease)
Patients must have adequate organ function, defined by the following laboratory results prior to first study treatment: * Absolute neutrophil count (ANC) ≥ 1500/mcL * Platelet count ≥ 100,000/mcL * AST/ALT ≤ 3X upper limit of normal (ULN) * Total bilirubin ≤ 1.5X ULN. Patients with known Gilbert's disease and a total bilirubin ≤ 3X ULN may be enrolled. * Creatinine ≤ 1.5X ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Memorial Sloan Kettering Cancer Center · New York, New York
- Memorial Sloan Kettering Nassau (All protocol activities) · Uniondale, New York
- Memorial Sloan Kettering Basking Ridge (All protocol activities) · Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (All protocol activities) · Middletown, New Jersey
- Memorial Sloan Kettering Bergen (All protocol activities) · Montvale, New Jersey
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05691010 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior radiation therapy, chemotherapy, radiation therapy disqualifies patients from enrollment.
Are patients with POLE alterations eligible?
No. POLE pathogenic mutation is an exclusion criterion.
Are patients with MLH1 alterations eligible?
No. MLH1 loss is an exclusion criterion.
What disease stage is eligible?
Stage FIGO (2009) STAGE IIIA or FIGO (2009) STAGE IIIC1 is required.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages